One mechanism of resistance to T cell-targeting immunotherapies is loss of T cell effector activity (Pauken et al., 2016; Balança et al., 2021), whereby dysfunctional/exhausted CD8+ T cells fail to adequately clear cancer cells. This evidence concerns the gene CD8A and cancer.